Hepatocellular carcinoma (HCC) is a heterogeneous inflammation-driven malignancy,
which, despite significant advances in management, continues to portend a poor prognosis …

Regorafenib has anti-tumor activity in patients with unresectable hepatocellular carcinoma
(uHCC) with potential immunomodulatory effects, suggesting that its combination with …

Myeloid derived suppressor cells (MDSC) are a heterogenous population of immature
myeloid cells that accumulate in tumor bearing host and migrate to lymphoid organs and …

Objective The current treatment for hepatocellular carcinoma (HCC) to block angiogenesis
and immunosuppression provides some benefits only for a subset of patients with HCC, thus …

BACKGROUND The tumor immune microenvironment can provide prognostic and
therapeutic information. We aimed to develop noninvasive imaging biomarkers from …

Cholesterol is often enriched in tumor microenvironment (TME); however, its impact on
disease progression varies in different tissues and cells. Monocytes/macrophages (Mφ) are …

The spleen is an important site of hematopoietic stem/progenitor cell (HSPC)
preconditioning and tumor-promoting myeloid cell generation in cancer, but the regulatory …

Hepatocellular carcinoma (HCC) is one of the most common digestive system cancers
(DSCs) with a poor prognosis. Zinc‐regulated transporter (ZRT)/iron‐regulated transporter …

Myeloid cells are abundant and plastic immune cell subsets in the liver, to which pro-
tumorigenic, inflammatory and immunosuppressive roles have been assigned in the course …

Background IgA neutralizes pathogens to prevent infection at mucosal sites. However,
emerging evidence shows that IgA contributes to aggravating inflammation or dismantling …